News Sentiment

CABA sentiment intelligence

Cabaletta Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.83 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-4.9% over one week, -0.4% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Moderate Buy" by Analysts

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -4.9% Price reacting lower
Trend fit Trend active -0.4% over four weeks
Fair value -60.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 46
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 9
TradingView 8
simplywall.st 5
www.marketscreener.com 3
Insider Monkey 3
Finviz 2
TradingKey 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 11
Analyst action 5
Guidance 3
Balance sheet 2
Capital return 1
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 66
Insider Monkey Direct company coverage

Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy

This article lists the top 5 penny stocks for investors' portfolios, providing details for Cabaletta Bio Inc. (NASDAQ: CABA) as one example. It highlights the company's positive clinical data from its CAR T cell therapy for autoimmune diseases, production agreements, and future B

Tone
Positive 72/100
Event
Market update
Published
05 Jun 2026 21:00
Source
Insider Monkey
The Clinical Trial Vanguard Direct company coverage

Cabaletta Bio Reports 83% Response Rate for Rese-cel in Dermatomyositis

Cabaletta Bio announced an 83% response rate for its drug rese-cel in dermatomyositis patients during the RESET-Myositis trial, with responses maintained for up to 1.5 years. The company plans a 2027 BLA submission for dermatomyositis and is also pursuing systemic sclerosis with

Tone
Positive 75/100
Event
Market update
Published
05 Jun 2026 06:39
Source
The Clinical Trial Vanguard